IP Library Granted Patent US 9,303,041
Granted Patent B2
US 9,303,041 · App. 13/970,653 · Granted Apr 5, 2016

Haptens of olanzapine

Inventors: Matthew Garrett Donahue (Warrington, PA); Yong Gong (Warrington, PA); Rhys Salter (Doylestown, PA); Eric Hryhorenko (Hilton, NY); Thomas R. DeCory (Pittsford, NY); Bart Remmerie (Gent, BE); Banumathi Sankaran (Pittsford, NY)
Assignees: Janssen Pharmaceutica NV; Ortho-Clinical Diagnostics, Inc.
C07D495/04A61K47/4833A61K47/48246A61K47/48284C07K14/47C07K14/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,303,041
App. No.
13/970,653
Granted
Apr 5, 2016
Kind
B2
Abstract

The invention relates to compounds of Formula I, wherein R 1 , R 2 , and R 3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from olanzapine. The invention also relates to conjugates of an olanzapine hapten and a protein.

Claims (74)

1. The compound of Formula I:

wherein:

R 1 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 3 is H; provided that either R 1 or R 2 must be H, and further provided that R 1 and R 2 may not all be H simultaneously;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

2. The compound of claim 1 :

wherein:

R 1 is

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

3. The compound of claim 1

wherein:

R 1 is H,

R 2 is

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

4. The compound of claim 1

wherein:

R 1 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

5. The compound of claim 1

wherein:

R 1 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

R 3 is H;

m is 1, 2, 3, 4, or 5; and n is 1, 2, 3, 4, or 5.

6. The compounds of claim 1 , selected from the group consisting of:

7. The compound of claim 6 which is:

8. The compound of claim 6 which is:

9. A conjugate of the compound of claim 1 and an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

10. A conjugate of the compound of claim 2 and an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

11. A conjugate of the compound of claim 3 and an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

12. A conjugate of the compound of claim 4 and an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

13. A conjugate of the compound of claim 5 and an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

14. The conjugate of claim 9 wherein the compound is:

15. The conjugate of claim 9 wherein the compound is:

16. The conjugate of claim 9 wherein the compound is:

17. The conjugate of claim 9 wherein the compound is:

18. A product made by the process of contacting a compound of claim 1 with an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

19. A product made by the process of contacting a compound of claim 2 with an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

20. A product made by the process of contacting a compound of claim 3 with an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

21. A product made by the process of contacting a compound of claim 4 with an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

22. A product made by the process of contacting a compound of claim 5 with an immunogenic carrier, wherein the immunogenic carrier is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

23. The product of claim 18 wherein the compound is:

24. The product of claim 18 wherein the compound is:

25. The product of claim 18 wherein the compound is:

26. The product of claim 18 wherein the compound is:

27. The compound of claim 1

wherein:

R 1 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

 CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

28. A conjugate of the compound of claim 27 and an immunogenic carrier, wherein the immunogenic carrier is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

29. A product made by the process of contacting a compound of claim 27 with an immunogenic carrier, wherein the immunogenic carrier is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2016
From: ORTHO-CLINICAL DIAGNOSTICS, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 039615/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: REMMERIE, BART
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033668/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: GONG, YONG; SALTER, RHYS
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033668/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: DONAHUE, MATTHEW GARRETT
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033668/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: HRYHORENKO, ERIC; DECORY, THOMAS R.; SANKARAN, BANUMATHI
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 033669/0062 →
Continuity (2)
Provisional Application 61691454 · Aug 21, 2012
Related Publication 20140213766A1 · Jul 31, 2014